Jean-Michel Fournier Becomes the New CEO at Interaxon Inc. (Muse®)

Muse, the leading brain health platform built on innovative Electroencephalogram (EEG), announced that Jean-Michel Fournier has joined the company as Chief Executive Officer and member of the board. Fournier brings a wealth of experience in scaling high-growth companies and driving innovation in the health and wellness space. He succeeds Derek Luke, who now takes an advisory role.

Jean-Michel Fournier joins Interaxon from BODi (NYSE:BODY), the leading digital wellness and nutrition subscription company, where he served as President of Corporate Development & Strategic Partnerships. He also served as CEO of Les Mills Media, part of Les Mills International, one of the largest active fitness & wellness communities in the world. Prior to this, Fournier was the co-founder & CEO of the mobile and computer vision platform BitGym, and held several senior executive roles at UnitedHealth Group and Hewlett Packard.

“We are thrilled to welcome Jean-Michel to Interaxon,” said Lally Rementilla, Interaxon board chair and Managing Partner, IP-Backed Financing, BDC Capital. “His impressive track record of building and leading successful companies in the digital wellness and healthcare space, combined with his passion for using technology to improve people’s lives, makes him the ideal leader to guide Interaxon through its next phase of growth.”

“I am honored to be joining Interaxon at such an inflection point in the company’s history,” said Fournier. “With its patented mEEG platform, Interaxon has firmly established itself as a global leader in the brain health and neurotechnology space. I’m excited to work with such a talented team to drive even greater growth and support innovation that helps millions of people to improve their mental health and well being.”

Interaxon’s cornerstone product, The Muse headband, uses electroencephalography (EEG) sensors to monitor brain activity and provide real-time feedback to users about their mental state, including their level of focus, relaxation, and stress. The Muse headband has been used by individuals, researchers, and clinicians to improve mindfulness, mental health practices, and support neuroscience research and innovation. With Fournier at the helm, Interaxon is poised to expand its reach and impact, with a focus on developing new products and strategic partnerships that leverage the power of brain-sensing technology to address a wide range of health and wellness challenges.

“Jean-Michel’s experience and expertise in the wellness and healthcare industries will be invaluable as we continue to grow and innovate at Interaxon,” said Ariel Garten, Interaxon Co-founder & Chief Evangelist Officer. “We are excited to see the impact he will have on our company, our customers, and our mission of empowering people to live healthier, happier lives.”

SourceMuse

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.